TCON [NASD]
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own1.30% Shs Outstand19.61M Perf Week5.99%
Market Cap34.55M Forward P/E- EPS next Y-1.23 Insider Trans261.17% Shs Float18.10M Perf Month-20.63%
Income-33.10M PEG- EPS next Q-0.36 Inst Own46.80% Short Float0.90% Perf Quarter-26.56%
Sales0.30M P/S115.17 EPS this Y11.00% Inst Trans-1.88% Short Ratio1.55 Perf Half Y-38.75%
Book/sh0.14 P/B12.64 EPS next Y11.10% ROA-126.00% Target Price11.38 Perf Year-69.69%
Cash/sh- P/C- EPS next 5Y- ROE-292.20% 52W Range1.61 - 7.42 Perf YTD-36.10%
Dividend- P/FCF- EPS past 5Y40.00% ROI-216.40% 52W High-76.15% Beta1.85
Dividend %- Quick Ratio1.20 Sales past 5Y-36.90% Gross Margin- 52W Low10.14% ATR0.18
Employees19 Current Ratio1.20 Sales Q/Q- Oper. Margin- RSI (14)36.96 Volatility10.89% 9.74%
OptionableYes Debt/Eq0.25 EPS Q/Q-47.70% Profit Margin- Rel Volume0.44 Prev Close1.86
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume104.37K Price1.77
Recom1.90 SMA20-10.08% SMA50-25.07% SMA200-39.73% Volume45,929 Change-4.84%
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
May-16-22 08:05AM  
May-11-22 04:02PM  
May-04-22 08:05AM  
Apr-19-22 08:05AM  
Apr-08-22 05:02PM  
Mar-23-22 08:05AM  
Mar-15-22 04:02PM  
Mar-11-22 08:05AM  
Mar-10-22 08:05AM  
Mar-04-22 08:05AM  
Feb-02-22 08:05AM  
Jan-05-22 08:05AM  
Dec-27-21 08:00AM  
Nov-29-21 08:05AM  
Nov-11-21 08:05AM  
Nov-03-21 04:02PM  
Oct-27-21 08:05AM  
Oct-13-21 08:00AM  
Oct-11-21 01:27PM  
08:00AM  
Sep-13-21 08:05AM  
Sep-07-21 08:05AM  
07:29AM  
Sep-02-21 08:05AM  
Aug-11-21 04:02PM  
Aug-09-21 08:05AM  
Aug-03-21 08:05AM  
Jul-28-21 08:05AM  
Jul-21-21 10:30PM  
05:27PM  
Jul-20-21 08:05AM  
Jun-30-21 08:05AM  
Jun-29-21 08:05AM  
Jun-28-21 01:04PM  
Jun-18-21 10:08AM  
Jun-04-21 09:01AM  
Jun-01-21 08:05AM  
May-25-21 08:05AM  
May-20-21 08:05AM  
May-05-21 04:03PM  
02:45PM  
08:25AM  
May-03-21 08:05AM  
Apr-28-21 08:05AM  
Apr-26-21 08:00AM  
Mar-23-21 08:05AM  
Mar-09-21 08:05AM  
Mar-08-21 08:05AM  
Mar-02-21 08:05AM  
Feb-25-21 04:03PM  
02:30PM  
Feb-18-21 08:05AM  
Jan-28-21 11:40AM  
Jan-19-21 08:05AM  
Jan-06-21 08:05AM  
Dec-30-20 08:05AM  
Dec-29-20 08:05AM  
Dec-22-20 08:05AM  
Dec-10-20 08:05AM  
Dec-04-20 08:29AM  
Dec-03-20 09:14AM  
Nov-30-20 04:17PM  
Nov-23-20 08:05AM  
Nov-16-20 09:45AM  
Nov-10-20 04:03PM  
02:45PM  
Nov-03-20 08:05AM  
Oct-26-20 08:05AM  
Sep-25-20 11:29AM  
Sep-21-20 08:05AM  
Sep-10-20 08:05AM  
Sep-09-20 11:51AM  
Sep-03-20 08:05AM  
Aug-31-20 08:05AM  
Aug-27-20 08:05AM  
Aug-25-20 11:49AM  
Aug-24-20 11:59AM  
Aug-17-20 11:08AM  
08:38AM  
08:05AM  
Aug-05-20 04:05PM  
Aug-03-20 08:05AM  
Jul-29-20 04:05PM  
Jul-16-20 08:15AM  
Jul-13-20 08:15AM  
Jun-22-20 02:19PM  
Jun-11-20 10:56PM  
Jun-05-20 02:48PM  
Jun-01-20 08:05AM  
May-29-20 08:20AM  
May-14-20 08:32AM  
May-13-20 04:04PM  
May-11-20 08:15AM  
May-06-20 04:05PM  
Apr-24-20 08:15AM  
Apr-14-20 08:15AM  
Apr-06-20 08:15AM  
Mar-19-20 08:15AM  
Mar-18-20 03:29AM  
Mar-16-20 08:15AM  
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerMay 10Buy1.769,70017,0322,934,600May 10 07:58 PM
THEUER CHARLESPresident and CEOMay 09Buy1.8510,00018,500252,018May 11 06:00 AM
THEUER CHARLESPresident and CEOMay 06Buy1.972,5004,925242,018May 10 06:00 AM
THEUER CHARLESPresident and CEOApr 29Buy1.975,0009,854239,518May 03 06:00 AM
Opaleye Management Inc.10% OwnerApr 25Buy2.1810,77723,4972,920,000Apr 25 05:55 PM
Opaleye Management Inc.10% OwnerApr 22Buy1.987,10014,0582,926,100Apr 29 06:27 PM
Opaleye Management Inc.10% OwnerApr 22Buy2.2442,00093,9412,910,000Apr 25 05:55 PM
THEUER CHARLESPresident and CEOApr 21Buy2.304,50010,350234,518Apr 25 06:00 AM
Opaleye Management Inc.10% OwnerApr 14Buy2.5012,69631,7302,872,296Apr 14 06:13 PM
Opaleye Management Inc.10% OwnerApr 13Buy2.507,34518,3612,862,296Apr 14 06:13 PM
Opaleye Management Inc.10% OwnerApr 12Buy2.4818,09844,8272,857,296Apr 12 07:38 PM
Opaleye Management Inc.10% OwnerApr 11Buy2.429,10022,0192,844,198Apr 12 07:38 PM
THEUER CHARLESPresident and CEOApr 08Buy2.502,0005,000226,518Apr 12 06:00 AM
THEUER CHARLESPresident and CEOMar 30Buy2.704,00010,800224,518Apr 01 06:05 AM
Brown Scott B.Chief Financial OfficerMar 29Buy2.821,0002,8208,628Mar 30 07:20 AM
THEUER CHARLESPresident and CEOMar 21Buy2.451,2002,940220,518Mar 23 06:00 AM
Opaleye Management Inc.10% OwnerMar 16Buy2.202,2354,9172,837,735Mar 17 04:05 PM
Opaleye Management Inc.10% OwnerJan 28Buy2.205001,1002,820,500Jan 31 04:05 PM
Opaleye Management Inc.10% OwnerJan 24Buy2.0517,36335,6032,835,000Jan 24 06:18 PM
Opaleye Management Inc.10% OwnerJan 21Buy2.1935,00076,8112,820,000Jan 24 06:18 PM
Opaleye Management Inc.10% OwnerJan 20Buy2.2521,31247,9522,790,000Jan 21 04:00 PM
Opaleye Management Inc.10% OwnerJan 19Buy2.2423,68853,0802,770,000Jan 21 04:00 PM
Opaleye Management Inc.10% OwnerDec 29Buy2.5152,325131,3622,750,000Dec 29 07:14 PM
Opaleye Management Inc.10% OwnerDec 28Buy2.6320,12552,9502,717,675Dec 29 04:05 PM
Opaleye Management Inc.10% OwnerDec 27Buy2.9287,325255,1032,592,371Dec 29 04:05 PM
Opaleye Management Inc.10% OwnerDec 15Buy2.4321,96453,2872,517,371Dec 16 04:01 PM
Opaleye Management Inc.10% OwnerDec 14Buy2.5342,000106,3442,497,371Dec 15 04:05 PM
Opaleye Management Inc.10% OwnerDec 13Buy2.6415,20440,1542,462,371Dec 15 04:05 PM
Opaleye Management Inc.10% OwnerDec 06Buy2.2622,73351,4742,448,371Dec 07 04:05 PM
Opaleye Management Inc.10% OwnerDec 03Buy2.3089,274204,9112,428,371Dec 07 04:05 PM
Opaleye Management Inc.10% OwnerDec 02Buy2.3510,50024,6602,348,371Dec 03 05:14 PM
Opaleye Management Inc.10% OwnerDec 01Buy2.4050,000120,1602,338,371Dec 03 05:14 PM
THEUER CHARLESPresident and CEONov 19Buy2.823,5009,870219,318Nov 22 04:21 PM
THEUER CHARLESPresident and CEONov 18Buy2.886811,961215,818Nov 22 04:21 PM
THEUER CHARLESPresident and CEONov 05Buy3.414,00013,655215,137Nov 09 07:00 AM
THEUER CHARLESPresident and CEOAug 16Buy3.563,00010,680207,732Aug 18 06:05 AM
Brown Scott B.Chief Financial OfficerAug 13Buy3.691,0003,6957,628Aug 17 05:01 PM
PELLETIER SAUNDRA LDirectorJul 26Buy3.826,54525,00212,045Jul 27 06:00 AM
LARUE WILLIAM RDirectorJul 26Buy3.826,54525,0027,883Jul 27 06:00 AM